Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.40 |
| ▸ | CA1 | P00915 | 12/20 | 0.40 |
| ▸ | CA4 | P22748 | 6/20 | 0.40 |
| ▸ | CA6 | P23280 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 11/20 | 0.36 |
| ▸ | CA12 | O43570 | 8/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.36 |
| ▸ | CA5A | P35218 | 4/20 | 0.36 |
| ▸ | CA7 | P43166 | 4/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015590 | 1.00 | CA2 (0.40) | CA2CA1CA4CA6CA9 | |
| SCHEMBL30253017 | 0.78 | LOX (0.41) | LMNA | |
| SCHEMBL12753748 | 0.78 | ALDH1A1 (0.44) | — | |
| SCHEMBL1404067 | 0.78 | LOX (0.41) | LMNA | |
| SCHEMBL17647899 | 0.76 | NOS3 (0.43) | CA2CA1CA4CA6CA9 | |
| SCHEMBL19786784 | 0.75 | CDK1 (0.33) | — | |
| SCHEMBL6501463 | 0.74 | CYP3A4 (0.43) | CA2CA1CA4CA6CA9 | |
| SCHEMBL9376409 | 0.74 | CA2 (0.38) | CA2CA1CA4CA6CA9 | |
| SCHEMBL21256375 | 0.74 | CA2 (0.38) | CA2CA1CA4CA6CA9 | |
| SCHEMBL6449500 | 0.74 | SLC40A1 (0.47) | CA2CA1CA4CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMA (US) | 2024-11-07 | — | — | US | disclosed |
| CN-114585628-B | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012000896-A2 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000896-A2 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | WO | disclosed |
| CN-101842362-A | Benzothiazole compounds | INST MEDICAL W & E HALL | 2010-09-22 | — | — | CN | disclosed |
| US-20100197711-A1 | BENZOTHIAZOLE COMPOUNDS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-08-05 | — | — | US | disclosed |
| EP-2193127-A1 | BENZOTHIAZOLE COMPOUNDS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009039553-A1 | BENZOTHIAZOLE COMPOUNDS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-04-02 | — | — | WO | disclosed |
| WO-2005058299-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197711-A1 | BENZOTHIAZOLE COMPOUNDS | BAD, BCL2, BAX | CA2 3305/4885CA1 3529/4885CA4 4253/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CA2 2673/4885CA1 4798/4885CA4 4267/4885 |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | CA2 1541/4885CA1 4785/4885CA4 2836/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | CA2 3700/4885CA1 4774/4885CA4 4053/4885 |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | CA2 2526/4885CA1 2461/4885CA4 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.